In Toulouse, a cancer vaccine gives “first encouraging results”
Patients, researchers and doctors place some of their hope on the design ofa cancer vaccine. Several teams of researchers, French and foreign, are trying to find a solution to control the progression of the disease, and in particular to avoid relapses.
Last Wednesday, the IUCT-Oncopole of Toulouse, the biotechnology company Transgene and the patient association Corasso presented the progress of two phase I trials conducted in Toulouse. And the first results are “encouraging”, according to a statement sent to the press on the occasion of the world day against the cancer.
Launched in 2020 at the IUCT-Oncopole and the Institut Curie, the trials aimed at evaluating the efficacy and safety of the personalized TG4050 vaccine. Like everyone therapeutic vaccinesit is designed “to promote the immune system of patients, in order to recognize and destroy tumors”, informs the press release.
Transgene’s approach “is based on genetic mutations specific to the patient’s tumor to educate their immune defences. It uses artificial intelligence to be able to provide an individualized vaccine within the medical deadlines. In very simple terms, the vaccineas this is the case for other illnessessomehow tries to help the patient’s body defend itself against pathology.
One of the clinical assessments is for patients with a ENT cancer not virus-induced. The second (…)
Cystic fibrosis: Kaftrio, the treatment that is revolutionizing the lives of patients
Covid: good news, the decrease in the epidemic continues in France
Flu, shingles… The link between certain viruses and Alzheimer’s confirmed by a new study
How many hours of sleep do you need to be healthy?
Insomnia: the “mental walk”, this new method that helps to find sleep